Hims & Hers Health announced plans to expand its weight loss program into Canada in 2026, coinciding with the anticipated availability of generic semaglutide following the lapse of Novo Nordisk's patent. The company highlighted that generic versions of semaglutide, including those similar to Ozempic and Wegovy, will be significantly cheaper than branded counterparts, which cost over C$200 per month. This move aligns with the opening of the generic semaglutide drug market in Canada. Following the announcement, Hims & Hers shares rose, supported by increased trading activity and a notable surge in call options volume, despite no recent additional company news. Market analysts noted the stock's upward momentum, with technical indicators suggesting potential further gains.